Northwest Compounding Pharmacy (Hiers Enterprises, LLC), Roseburg, OR

Is Northwest Compounding Pharmacy (Hiers Enterprises, LLC) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Northwest Compounding Pharmacy (Hiers Enterprises, LLC) hold a Oregon pharmacy license?

State board of pharmacy records for Oregon are not checked: the board lists 2025 and 2026 actions in a script-driven table and older actions only on request, and its license lookup is an interactive search.

Has Northwest Compounding Pharmacy (Hiers Enterprises, LLC) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Sep 22, 2022), 1 state referral letter (Jun 30, 2023) and 1 FMD-145 letter (Jun 30, 2023) for Northwest Compounding Pharmacy (Hiers Enterprises, LLC). State board of pharmacy records for Oregon are not checked: the board lists 2025 and 2026 actions in a script-driven table and older actions only on request, and its license lookup is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Hiers Enterprises, LLC; Northwest Compounding Pharmacy
Location
Roseburg, OR
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Jun 30, 2023
FDA Data Dashboard inspections
2 inspections: 1 VAI, 1 NAI; 2 published Form 483s
Form 483 text on this page
1 Form 483, 10 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Hiers Enterprises, LLC, (dba Northwest Compounding Pharmacy), a 503A facility, with 4 dated actions.

Document
Jun 30, 2023FMD-145 letterFMD-145 Letter Issued 06/30/2023Not linked by FDA
Jun 30, 2023State referral letterReferral Letter to the Oregon Board of Pharmacy Issued 06/30/2023FDA copy (archived)
Sep 22, 2022Untitled letterUntitled Letter Issued 09/22/2022fda.gov
Nov 10, 2021Form 483483 Issued 11/10/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Hiers Enterprises, LLC, Roseburg, OR (FEI number 3014745182), matched to this page by exact name, city and state. It lists 2 inspections: 1 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 16, 2022No Action Indicated (NAI)Drug Quality Assurance (Drugs)30147451821173041
Nov 10, 2021Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30147451821157204

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 10 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Nov 14, 2018: 10 observations

Firm on the cover
, 1350 NE Stephens Street, Suite fl 42 CITY, SfATE, ZIP COOE, COUNTRY Roseburg, OR 97470-6410
FEI number
3014745182
Establishment type on the cover
Producer of sterile and non-sterile drug products
FDA district office on the cover
22215 26th Ave SE Suite 210 Bothell, WA 98021
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, operators demonstrate inadequate technique during non-sterile to sterile production operations while in an unclassified zone and while under laminar airflow. For example:

A) On 10/29/2018 during production ofM.I.C B. Vitamins (25/50/1/1/1 MG/ML Liquid) for IM injection, lot

10292018@15, formula ID: 6814, with a BUD ofOl/27/2019, the Sterile Drug Tech was observed:

-In an unclassified space, drug components were mixed and drawn from an unsterilized,! {15) (4)into a sterile syringe. The syringe was then directly placed into an unsterilized I {15 {4l ontainer for final transport from the unclassified space into the IS05 classified zone

B) On 10/29/2018 during production ofM.I.C B. Vitamins (25/50/1/1/IMG/ML Liquid), lot 10292018@15, formula ID: 6814, with a BUD ofOl/27/2019, the Pharmacist in charge (PIC) was observed:

-Transporting in-process drug product in a sterile syringe via an unsterilized! -(6) ( 4 );ontainer from the unclassified zone into the IS08 classified anteroom while donning non-sterile gloves. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Clothing of personnel engaged in the of drug products is not appropriate for the duties they perform.

Specifically,

During production on 10/29/2018 of Glutathione Sterile l00MG/ML Solution, Lot: 10292018@17, formula ID: 10586, with a BUD of0I/27/2019, the following was observed:

- The Pharmacist in charge was observed to don a previously worn, non-sterile gown hanging on the wall of the ISO 8 classified anteroom that was ill fitting, exposing both skin (unshaven neck and eyes without cover) and personal clothing inside the ISOS classified LAFH during production.

- The Pharmacist in charge was observed leaning into the ISO 5 classified LAFH during aseptic processing with other non-sterile garbing such as gloves, face mask and hairnet.

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, the ISO classified areas lack appropriate data to support appropriate installation certification and continued ISO classifications.

A) On 10/29/2018 a ceiling tile was observed to be loose in the ISO7 classified buffer zone, exposing sterile drug production areas to unclassified air. Additionally, on 11/01/2018 the HEPA system was viewed via an adjacent unclassified area. Openings were observed in the light fixture that would allow unclassified air into the cleanroom.

B) Environmental monitoring of ISO classified zones is conducted on <Redacted B4> basis only. Monitoring to prevent or detect incursion into the ISO classified zones is not ongoing at your facility and no risk assessment of your facility or processes has ever been conducted. EM data provided is incomplete.

C) Personnel monitoring does not include samples taken from the gloved hands of employees after performing sterile drug production inside the 1S05 classified zone at any time. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A) Non-sterile <Redacted B4> is used for the cleaning and sanitation of the ISO classified zones. This <Redacted B4> is diluted from <Redacted B4> No procedures were provided to demonstrate how said dilution is conducted nor data provided to demonstrate <Redacted B4> concentration is achieved.

B) Non-sterile wipes are used to clean the ISOS classified zone.

C) Your firm is using <Redacted B4> as a sporicidal agent. No data was provided to establish the effectiveness of <Redacted B4> as a sporicidal disinfectant and no dwell time has been established or proceduralized.

D) Your firm is using sponges and green scratch pads to clean equipment such as beakers, stirring rods, raw ingredient storage containers and measuring utensils used in the production of sterile drug products. The sanitation of equipment used in the production of sterile drug products is purportedly conducted using <Redacted B4> however there is no procedure to demonstrate an adequate process and no record is kept of instrument cleaning or sanitation. ...

Read the full 483 (PDF on fda.gov)

Observation 5

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, the Beyond Use Dates (BUD) extended or otherwise used at your facility, are not associated with any appropriate study intended to demonstrate the stability of finished drug products for characteristics such as potency or sterility.

M.I.C B. Vitamins (25/50/1/1/IMG/ML Liquid) lot:10292018@15 for IM injection, formula ID: 6814, produced on 10/29/2018 was assigned a BUD of01/27/2019 (90 Days). When asked to provide, the source ofdata for assigning said BUO's the "Pharmacist In Charge" downloaded a formula sheet from <Redacted B4> website. The firm is currently not following <Redacted B4> suggested formula processes or guidelines as recommended. Furthermore, under <Redacted B4> formula provided guidelines, in the absence of passing a sterility test under high-risk conditions (non-sterile to sterile) storage periods cannot exceed the following time periods:

- Controlled Room Temp (not more than non <Redacted B4>

- Cold Temp (not more than <Redacted B4> ...

Read the full 483 (PDF on fda.gov)

Observation 6

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to detennine conformance to such requirements.

Specifically, the firm has not established a testing program for any of its sterile drug products in order to regularly demonstrate products are sterile and pyrogen free.

Observation 7

Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.

Specifically, microbial limits have not been established for non-sterile finished drug products produced at your facility and products are not tested for the presence of objectionable microorganisms.

Observation 8

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.

Specifically, your firm does not conduct any potency testing of sterile or non-sterile drug products produced at your facility. No records could be provided to demonstrate established acceptance criteria data.

Observation 9

Each lot of a component that is liable to microbiological contamination that is objectionable in view of its intended use is not subjected to microbiological tests before use.

Specifically,

A)<Redacted B4> used in the production of sterile and non-sterile drug products is not tested before use for the presence of microbiological contamination. The <Redacted B4> comes in commercially available 5 gallon containers and is extracted using are <Redacted B4> that is attached at the top of the 5 gallon container. <Redacted B4> from the 5 gallon container and stored in a <Redacted B4> in an unclassified zone for use in production until empty. For example:

- On I0/29/2018 during production of Glutathione Sterile IO0MG/ML Solution, Lot: !0292018@17, formula ID: 10586, with a BUD of0l/27/2019, the Sterile Lab Tech was observed using <Redacted B4> stored in the <Redacted B4> as an ingredient.

- On 10/29/2018 during production ofM.I.C B. Vitamins (25/50/1/1/lMG/ML Liquid) for IM injection, lot 10292018@15, formula ID: 6814, with a BUD of01/27/2019, the Sterile Drug Tech was observed using <Redacted B4> stored in the <Redacted B4> : as an ingredient. ...

Read the full 483 (PDF on fda.gov)

Observation 10

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically, your ISO classified zones lack sufficient data to substantiate the current classifications. For example:

- Validation of your HEPA system has never been conducted.

~<Redacted B4> HEPA integrity testing results do not provide adequate data to support ongoing qualification of your system.

- Lighting equipment used in your aseptic processing area was observed to be insufficient. Light fixtures used are not designed to maintain ceiling integrity and prevent infiltration of particulate into the clean room under positive pressure.

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Oregon are not checked: the board lists 2025 and 2026 actions in a script-driven table and older actions only on request, and its license lookup is an interactive search.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.